Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | GCGR | P47871 | 2/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28758651 | 1.00 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL27647803 | 0.87 | GCGR (0.43) | MAPK14MAPK13MAPK12MAPK11SRC | |
| SCHEMBL4805328 | 0.87 | GCGR (0.43) | MAPK14MAPK13MAPK12MAPK11SRC | |
| SCHEMBL5005154 | 0.84 | NOTUM (0.45) | MAPK14MAPK11CSNK1DGCGR | |
| SCHEMBL14181042 | 0.81 | KDM4E (0.47) | MAPK14SRCBRAFKDRGCGR | |
| SCHEMBL4046888 | 0.78 | PTGS2 (0.40) | — | |
| SCHEMBL4806059 | 0.78 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL4803668 | 0.74 | MAPT (0.39) | KDRGCGR | |
| SCHEMBL27399203 | 0.71 | RPS6KA3 (0.41) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL27535145 | 0.70 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1697370-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| CN-1918165-A | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | CN | disclosed |
| EP-1697370-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063761-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050143381-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BROSTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143381-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, CCKBR | MAPK14 2315/4885MAPK13 1689/4885MAPK12 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.